{"status": "Succeeded", "recognitionResults": [{"page": 1, "clockwiseOrientation": 0.07, "width": 1700, "height": 2236, "unit": "pixel", "lines": [{"boundingBox": [1338, 212, 1448, 212, 1448, 260, 1336, 257], "text": "107", "words": [{"boundingBox": [1336, 210, 1444, 211, 1444, 259, 1335, 258], "text": "107"}]}, {"boundingBox": [288, 266, 818, 268, 817, 302, 287, 300], "text": "FDA Conference Call: August 13, 2002", "words": [{"boundingBox": [290, 269, 350, 269, 351, 299, 291, 298], "text": "FDA"}, {"boundingBox": [359, 269, 517, 270, 517, 301, 360, 299], "text": "Conference"}, {"boundingBox": [523, 270, 596, 270, 596, 302, 523, 301], "text": "Call:"}, {"boundingBox": [604, 270, 703, 270, 703, 302, 604, 302], "text": "August"}, {"boundingBox": [709, 270, 748, 269, 747, 302, 709, 302], "text": "13,"}, {"boundingBox": [754, 269, 818, 268, 817, 302, 753, 302], "text": "2002"}]}, {"boundingBox": [1238, 307, 1237, 170, 1259, 170, 1259, 306], "text": "PENGAD 800-631-698", "words": [{"boundingBox": [1240, 307, 1239, 250, 1258, 249, 1259, 307], "text": "PENGAD"}, {"boundingBox": [1239, 246, 1238, 172, 1259, 170, 1258, 245], "text": "800-631-698", "confidence": "Low"}]}, {"boundingBox": [1328, 158, 1417, 158, 1416, 187, 1327, 186], "text": "EXHIBIT", "words": [{"boundingBox": [1328, 158, 1416, 159, 1415, 188, 1328, 188], "text": "EXHIBIT"}]}, {"boundingBox": [285, 340, 502, 341, 501, 372, 284, 370], "text": "FDA Personnel:", "words": [{"boundingBox": [289, 340, 350, 341, 351, 370, 289, 371], "text": "FDA"}, {"boundingBox": [360, 341, 501, 343, 502, 372, 361, 370], "text": "Personnel:"}]}, {"boundingBox": [284, 408, 872, 412, 871, 447, 283, 443], "text": "Jeri El-Hage, Ph.D., Toxicology Team Leader", "words": [{"boundingBox": [288, 409, 333, 410, 334, 443, 289, 442], "text": "Jeri"}, {"boundingBox": [340, 410, 452, 412, 452, 445, 340, 443], "text": "El-Hage,"}, {"boundingBox": [458, 412, 544, 413, 545, 446, 459, 445], "text": "Ph.D.,"}, {"boundingBox": [551, 413, 697, 413, 698, 446, 551, 446], "text": "Toxicology"}, {"boundingBox": [703, 413, 768, 413, 769, 446, 704, 446], "text": "Team"}, {"boundingBox": [777, 413, 871, 412, 872, 446, 778, 446], "text": "Leader"}]}, {"boundingBox": [285, 444, 662, 449, 661, 483, 284, 477], "text": "Jena Weber, Project Manager", "words": [{"boundingBox": [288, 445, 345, 445, 345, 479, 287, 479], "text": "Jena"}, {"boundingBox": [352, 445, 441, 447, 440, 480, 351, 479], "text": "Weber,"}, {"boundingBox": [448, 447, 539, 448, 537, 481, 446, 480], "text": "Project"}, {"boundingBox": [545, 448, 661, 451, 659, 483, 544, 481], "text": "Manager"}]}, {"boundingBox": [287, 540, 520, 543, 519, 575, 286, 573], "text": "TPNA Personnel:", "words": [{"boundingBox": [290, 542, 370, 544, 370, 574, 291, 571], "text": "TPNA"}, {"boundingBox": [379, 544, 521, 543, 519, 575, 379, 574], "text": "Personnel:"}]}, {"boundingBox": [282, 612, 1074, 613, 1073, 648, 281, 647], "text": "David Baron, Ph.D., Director, Nonclinical Safety and Efficacy", "words": [{"boundingBox": [286, 615, 365, 615, 364, 645, 286, 644], "text": "David"}, {"boundingBox": [370, 615, 456, 615, 456, 645, 370, 645], "text": "Baron,"}, {"boundingBox": [462, 615, 544, 615, 544, 645, 462, 645], "text": "Ph.D.,"}, {"boundingBox": [550, 615, 666, 615, 665, 646, 550, 645], "text": "Director,"}, {"boundingBox": [671, 615, 818, 614, 817, 647, 671, 646], "text": "Nonclinical"}, {"boundingBox": [824, 614, 906, 614, 905, 647, 823, 647], "text": "Safety"}, {"boundingBox": [912, 614, 959, 614, 958, 647, 911, 647], "text": "and"}, {"boundingBox": [965, 614, 1074, 613, 1073, 648, 964, 648], "text": "Efficacy"}]}, {"boundingBox": [284, 648, 844, 650, 843, 682, 283, 680], "text": "Janet Haskins, Manager, Regulatory Affairs", "words": [{"boundingBox": [288, 649, 353, 650, 352, 681, 286, 680], "text": "Janet"}, {"boundingBox": [359, 650, 468, 651, 467, 681, 358, 681], "text": "Haskins,"}, {"boundingBox": [474, 651, 596, 651, 596, 682, 473, 681], "text": "Manager,"}, {"boundingBox": [602, 651, 745, 651, 746, 682, 602, 682], "text": "Regulatory"}, {"boundingBox": [751, 651, 843, 650, 844, 683, 752, 682], "text": "Affairs"}]}, {"boundingBox": [285, 682, 734, 684, 733, 718, 284, 716], "text": "Pat Frank, Ph.D., TPNA Consultant", "words": [{"boundingBox": [286, 684, 328, 684, 327, 717, 285, 716], "text": "Pat"}, {"boundingBox": [335, 684, 415, 684, 414, 717, 333, 717], "text": "Frank,"}, {"boundingBox": [422, 684, 507, 684, 506, 717, 421, 717], "text": "Ph.D.,"}, {"boundingBox": [513, 684, 594, 685, 593, 717, 512, 717], "text": "TPNA"}, {"boundingBox": [602, 685, 734, 687, 733, 717, 601, 717], "text": "Consultant"}]}, {"boundingBox": [287, 794, 1417, 796, 1416, 832, 286, 831], "text": "This teleconference was held as a follow-up to a discussion between TPNA and the", "words": [{"boundingBox": [289, 797, 348, 797, 348, 829, 289, 829], "text": "This"}, {"boundingBox": [354, 797, 545, 799, 545, 831, 354, 829], "text": "teleconference"}, {"boundingBox": [553, 799, 608, 800, 608, 831, 553, 831], "text": "was"}, {"boundingBox": [615, 800, 676, 800, 676, 831, 614, 831], "text": "held"}, {"boundingBox": [684, 800, 716, 800, 716, 832, 684, 831], "text": "as"}, {"boundingBox": [722, 800, 744, 800, 743, 832, 722, 832], "text": "a"}, {"boundingBox": [752, 800, 879, 800, 879, 832, 752, 832], "text": "follow-up"}, {"boundingBox": [890, 800, 919, 800, 919, 832, 889, 832], "text": "to"}, {"boundingBox": [928, 800, 949, 800, 948, 832, 927, 832], "text": "a"}, {"boundingBox": [962, 800, 1091, 799, 1090, 832, 961, 832], "text": "discussion"}, {"boundingBox": [1099, 799, 1209, 798, 1208, 832, 1098, 832], "text": "between"}, {"boundingBox": [1222, 798, 1302, 797, 1301, 832, 1221, 832], "text": "TPNA"}, {"boundingBox": [1315, 797, 1368, 796, 1367, 832, 1314, 832], "text": "and"}, {"boundingBox": [1374, 796, 1416, 796, 1416, 832, 1373, 832], "text": "the"}]}, {"boundingBox": [289, 832, 1410, 833, 1409, 866, 288, 865], "text": "Agency on July 31, 2002. The purpose of this call was so that Dr. El-Hage could expand", "words": [{"boundingBox": [289, 833, 384, 833, 384, 866, 289, 866], "text": "Agency"}, {"boundingBox": [391, 833, 425, 834, 425, 866, 391, 866], "text": "on"}, {"boundingBox": [431, 834, 486, 834, 486, 866, 431, 866], "text": "July"}, {"boundingBox": [492, 834, 533, 834, 532, 866, 492, 866], "text": "31,"}, {"boundingBox": [539, 834, 624, 834, 624, 866, 539, 866], "text": "2002."}, {"boundingBox": [630, 834, 676, 834, 676, 866, 630, 866], "text": "The"}, {"boundingBox": [683, 834, 784, 834, 784, 866, 683, 866], "text": "purpose"}, {"boundingBox": [791, 834, 818, 834, 818, 866, 791, 866], "text": "of"}, {"boundingBox": [825, 834, 873, 834, 873, 866, 825, 866], "text": "this"}, {"boundingBox": [880, 834, 928, 834, 928, 866, 880, 866], "text": "call"}, {"boundingBox": [935, 834, 985, 834, 986, 866, 935, 866], "text": "was"}, {"boundingBox": [992, 834, 1019, 834, 1019, 866, 992, 866], "text": "so"}, {"boundingBox": [1026, 834, 1074, 834, 1074, 866, 1026, 866], "text": "that"}, {"boundingBox": [1081, 834, 1125, 834, 1125, 866, 1081, 866], "text": "Dr."}, {"boundingBox": [1131, 834, 1237, 834, 1237, 867, 1132, 866], "text": "El-Hage"}, {"boundingBox": [1244, 833, 1315, 833, 1316, 867, 1244, 867], "text": "could"}, {"boundingBox": [1322, 833, 1409, 833, 1409, 867, 1322, 867], "text": "expand"}]}, {"boundingBox": [285, 868, 1415, 867, 1416, 901, 286, 902], "text": "upon the nonclinical data related to dual PPAR agonists that were discussed with TPNA", "words": [{"boundingBox": [286, 870, 351, 870, 351, 901, 287, 900], "text": "upon"}, {"boundingBox": [356, 870, 398, 870, 398, 901, 357, 901], "text": "the"}, {"boundingBox": [404, 870, 553, 869, 554, 902, 404, 901], "text": "nonclinical"}, {"boundingBox": [559, 869, 610, 869, 610, 902, 559, 902], "text": "data"}, {"boundingBox": [616, 869, 704, 869, 705, 902, 616, 902], "text": "related"}, {"boundingBox": [710, 869, 740, 869, 740, 902, 711, 902], "text": "to"}, {"boundingBox": [750, 869, 801, 869, 801, 902, 750, 902], "text": "dual"}, {"boundingBox": [807, 869, 885, 869, 885, 902, 807, 902], "text": "PPAR", "confidence": "Low"}, {"boundingBox": [897, 869, 1003, 868, 1003, 902, 897, 902], "text": "agonists"}, {"boundingBox": [1009, 868, 1060, 868, 1060, 902, 1009, 902], "text": "that"}, {"boundingBox": [1066, 868, 1133, 868, 1132, 902, 1066, 902], "text": "were"}, {"boundingBox": [1139, 868, 1261, 868, 1260, 901, 1138, 902], "text": "discussed"}, {"boundingBox": [1267, 868, 1326, 868, 1325, 901, 1266, 901], "text": "with"}, {"boundingBox": [1334, 868, 1412, 868, 1411, 900, 1333, 901], "text": "TPNA"}]}, {"boundingBox": [278, 902, 501, 901, 502, 937, 279, 938], "text": "on July 31, 2002.", "words": [{"boundingBox": [286, 904, 319, 903, 319, 937, 286, 938], "text": "on"}, {"boundingBox": [326, 903, 378, 902, 377, 935, 326, 937], "text": "July"}, {"boundingBox": [384, 902, 425, 903, 424, 935, 384, 935], "text": "31,"}, {"boundingBox": [431, 903, 501, 904, 499, 937, 430, 936], "text": "2002."}]}, {"boundingBox": [284, 975, 1414, 977, 1413, 1008, 283, 1006], "text": "Dr. El-Hage informed TPNA that in standard 2-year rat and mouse bioassay studies,", "words": [{"boundingBox": [286, 976, 334, 976, 334, 1006, 286, 1006], "text": "Dr."}, {"boundingBox": [340, 976, 450, 976, 450, 1007, 340, 1006], "text": "El-Hage"}, {"boundingBox": [456, 976, 578, 976, 578, 1007, 456, 1007], "text": "informed"}, {"boundingBox": [590, 976, 669, 977, 668, 1007, 590, 1007], "text": "TPNA"}, {"boundingBox": [683, 977, 737, 977, 736, 1007, 682, 1007], "text": "that"}, {"boundingBox": [743, 977, 771, 977, 770, 1007, 742, 1007], "text": "in"}, {"boundingBox": [781, 977, 895, 977, 894, 1007, 780, 1007], "text": "standard"}, {"boundingBox": [901, 977, 987, 977, 986, 1007, 900, 1007], "text": "2-year"}, {"boundingBox": [993, 977, 1036, 977, 1034, 1008, 992, 1007], "text": "rat"}, {"boundingBox": [1042, 977, 1092, 977, 1090, 1008, 1040, 1008], "text": "and"}, {"boundingBox": [1100, 977, 1188, 977, 1186, 1008, 1098, 1008], "text": "mouse"}, {"boundingBox": [1194, 977, 1308, 977, 1306, 1008, 1192, 1008], "text": "bioassay"}, {"boundingBox": [1318, 977, 1413, 977, 1410, 1009, 1316, 1008], "text": "studies,"}]}, {"boundingBox": [283, 1011, 1419, 1011, 1419, 1043, 284, 1043], "text": "several other dual PPAR agonists were shown to cause transitional cell tumors in the", "words": [{"boundingBox": [286, 1013, 380, 1013, 380, 1042, 286, 1042], "text": "several"}, {"boundingBox": [386, 1013, 460, 1013, 460, 1042, 386, 1042], "text": "other"}, {"boundingBox": [467, 1013, 524, 1013, 524, 1042, 467, 1042], "text": "dual"}, {"boundingBox": [530, 1013, 609, 1013, 609, 1042, 529, 1042], "text": "PPAR"}, {"boundingBox": [622, 1013, 731, 1013, 731, 1042, 622, 1042], "text": "agonists"}, {"boundingBox": [739, 1013, 803, 1013, 803, 1043, 739, 1042], "text": "were"}, {"boundingBox": [811, 1013, 896, 1012, 895, 1043, 810, 1043], "text": "shown"}, {"boundingBox": [905, 1012, 933, 1012, 933, 1043, 905, 1043], "text": "to"}, {"boundingBox": [945, 1012, 1018, 1012, 1018, 1043, 944, 1043], "text": "cause"}, {"boundingBox": [1026, 1012, 1173, 1012, 1172, 1043, 1025, 1043], "text": "transitional"}, {"boundingBox": [1178, 1012, 1231, 1012, 1231, 1043, 1178, 1043], "text": "cell"}, {"boundingBox": [1237, 1012, 1331, 1012, 1331, 1043, 1236, 1043], "text": "tumors"}, {"boundingBox": [1337, 1012, 1363, 1011, 1363, 1044, 1336, 1043], "text": "in"}, {"boundingBox": [1373, 1011, 1416, 1011, 1415, 1044, 1372, 1044], "text": "the"}]}, {"boundingBox": [282, 1046, 1419, 1045, 1420, 1078, 283, 1079], "text": "bladder and kidneys of male and female rats and male mice. Therefore, the Division is", "words": [{"boundingBox": [285, 1048, 382, 1048, 383, 1078, 286, 1078], "text": "bladder"}, {"boundingBox": [387, 1048, 437, 1048, 438, 1078, 389, 1078], "text": "and"}, {"boundingBox": [443, 1048, 547, 1049, 548, 1079, 444, 1078], "text": "kidneys"}, {"boundingBox": [553, 1049, 583, 1049, 584, 1079, 554, 1079], "text": "of"}, {"boundingBox": [588, 1049, 653, 1049, 655, 1079, 590, 1079], "text": "male"}, {"boundingBox": [659, 1049, 711, 1049, 712, 1079, 661, 1079], "text": "and"}, {"boundingBox": [716, 1049, 803, 1049, 804, 1079, 718, 1079], "text": "female"}, {"boundingBox": [809, 1049, 862, 1049, 863, 1079, 810, 1079], "text": "rats"}, {"boundingBox": [868, 1049, 915, 1049, 917, 1079, 869, 1079], "text": "and"}, {"boundingBox": [921, 1049, 986, 1048, 988, 1079, 923, 1079], "text": "male"}, {"boundingBox": [992, 1048, 1073, 1048, 1074, 1079, 994, 1079], "text": "mice."}, {"boundingBox": [1087, 1048, 1217, 1048, 1218, 1079, 1088, 1079], "text": "Therefore,"}, {"boundingBox": [1223, 1048, 1266, 1047, 1267, 1079, 1224, 1079], "text": "the"}, {"boundingBox": [1272, 1047, 1382, 1047, 1384, 1079, 1273, 1079], "text": "Division"}, {"boundingBox": [1388, 1047, 1418, 1046, 1419, 1079, 1390, 1079], "text": "is"}]}, {"boundingBox": [284, 1081, 1412, 1080, 1413, 1114, 285, 1115], "text": "considering the relevance of these findings to this pharmaceutical class of drugs. She", "words": [{"boundingBox": [287, 1084, 435, 1084, 434, 1114, 287, 1114], "text": "considering"}, {"boundingBox": [443, 1085, 486, 1085, 486, 1115, 442, 1115], "text": "the"}, {"boundingBox": [492, 1085, 620, 1085, 620, 1115, 492, 1115], "text": "relevance"}, {"boundingBox": [626, 1085, 658, 1085, 657, 1115, 626, 1115], "text": "of"}, {"boundingBox": [663, 1085, 734, 1085, 734, 1115, 663, 1115], "text": "these"}, {"boundingBox": [740, 1085, 849, 1085, 849, 1115, 740, 1115], "text": "findings"}, {"boundingBox": [855, 1085, 884, 1085, 884, 1115, 855, 1115], "text": "to"}, {"boundingBox": [892, 1085, 941, 1084, 941, 1115, 892, 1115], "text": "this"}, {"boundingBox": [947, 1084, 1146, 1083, 1147, 1115, 947, 1115], "text": "pharmaceutical"}, {"boundingBox": [1152, 1083, 1219, 1083, 1220, 1115, 1152, 1115], "text": "class"}, {"boundingBox": [1225, 1083, 1259, 1083, 1259, 1115, 1225, 1115], "text": "of"}, {"boundingBox": [1265, 1083, 1353, 1082, 1354, 1115, 1265, 1115], "text": "drugs."}, {"boundingBox": [1365, 1082, 1413, 1081, 1413, 1114, 1365, 1115], "text": "She"}]}, {"boundingBox": [286, 1117, 1415, 1116, 1416, 1150, 287, 1150], "text": "also noted that in follow-up unspecified mechanistic studies of the other dual PPAR", "words": [{"boundingBox": [287, 1119, 340, 1119, 341, 1149, 287, 1149], "text": "also"}, {"boundingBox": [348, 1119, 426, 1120, 426, 1150, 349, 1149], "text": "noted"}, {"boundingBox": [434, 1120, 489, 1120, 489, 1150, 434, 1150], "text": "that"}, {"boundingBox": [495, 1120, 523, 1120, 523, 1150, 495, 1150], "text": "in"}, {"boundingBox": [533, 1120, 660, 1121, 660, 1151, 533, 1150], "text": "follow-up"}, {"boundingBox": [671, 1121, 820, 1121, 821, 1151, 672, 1151], "text": "unspecified"}, {"boundingBox": [828, 1121, 985, 1120, 985, 1151, 829, 1151], "text": "mechanistic"}, {"boundingBox": [993, 1120, 1088, 1120, 1089, 1151, 993, 1151], "text": "studies"}, {"boundingBox": [1094, 1120, 1127, 1120, 1128, 1151, 1095, 1151], "text": "of"}, {"boundingBox": [1133, 1120, 1179, 1119, 1180, 1151, 1134, 1151], "text": "the"}, {"boundingBox": [1187, 1119, 1260, 1119, 1261, 1151, 1188, 1151], "text": "other"}, {"boundingBox": [1266, 1119, 1326, 1118, 1327, 1151, 1267, 1151], "text": "dual"}, {"boundingBox": [1331, 1118, 1409, 1117, 1410, 1150, 1333, 1151], "text": "PPAR"}]}, {"boundingBox": [285, 1156, 1155, 1157, 1154, 1187, 284, 1186], "text": "agonists, no evidence of irritation by crystalluria or calculi was noted.", "words": [{"boundingBox": [285, 1158, 397, 1157, 398, 1187, 286, 1186], "text": "agonists,"}, {"boundingBox": [403, 1157, 436, 1157, 438, 1187, 404, 1187], "text": "no"}, {"boundingBox": [442, 1157, 556, 1157, 557, 1187, 443, 1187], "text": "evidence"}, {"boundingBox": [561, 1157, 589, 1157, 591, 1187, 563, 1187], "text": "of"}, {"boundingBox": [595, 1157, 707, 1157, 708, 1187, 596, 1187], "text": "irritation"}, {"boundingBox": [712, 1157, 746, 1157, 747, 1187, 714, 1187], "text": "by"}, {"boundingBox": [751, 1157, 893, 1157, 895, 1187, 753, 1187], "text": "crystalluria"}, {"boundingBox": [899, 1157, 929, 1157, 930, 1187, 900, 1187], "text": "or"}, {"boundingBox": [934, 1157, 1020, 1158, 1021, 1187, 936, 1187], "text": "calculi"}, {"boundingBox": [1026, 1158, 1074, 1158, 1076, 1187, 1027, 1187], "text": "was"}, {"boundingBox": [1080, 1158, 1152, 1159, 1154, 1186, 1081, 1187], "text": "noted."}]}, {"boundingBox": [287, 1225, 1417, 1224, 1417, 1258, 288, 1259], "text": "Dr. El-Hage then described a tumor promoter-model study that was conducted by another", "words": [{"boundingBox": [288, 1226, 328, 1226, 328, 1258, 288, 1258], "text": "Dr."}, {"boundingBox": [334, 1226, 438, 1228, 438, 1259, 334, 1258], "text": "El-Hage"}, {"boundingBox": [444, 1228, 506, 1228, 506, 1259, 444, 1259], "text": "then"}, {"boundingBox": [512, 1228, 631, 1229, 630, 1259, 512, 1259], "text": "described"}, {"boundingBox": [637, 1229, 652, 1229, 651, 1259, 637, 1259], "text": "a"}, {"boundingBox": [658, 1229, 734, 1230, 734, 1259, 658, 1259], "text": "tumor"}, {"boundingBox": [741, 1230, 948, 1229, 947, 1259, 740, 1259], "text": "promoter-model"}, {"boundingBox": [954, 1229, 1022, 1229, 1021, 1259, 954, 1259], "text": "study"}, {"boundingBox": [1028, 1229, 1079, 1228, 1079, 1259, 1028, 1259], "text": "that"}, {"boundingBox": [1086, 1228, 1134, 1228, 1134, 1259, 1085, 1259], "text": "was"}, {"boundingBox": [1141, 1228, 1270, 1226, 1269, 1258, 1140, 1259], "text": "conducted"}, {"boundingBox": [1276, 1226, 1310, 1225, 1309, 1258, 1275, 1258], "text": "by"}, {"boundingBox": [1316, 1225, 1416, 1224, 1415, 1258, 1315, 1258], "text": "another"}]}, {"boundingBox": [285, 1263, 1357, 1261, 1358, 1293, 286, 1294], "text": "sponsor in which pioglitazone was administered. The study was designed as follows:", "words": [{"boundingBox": [286, 1265, 383, 1265, 384, 1293, 287, 1293], "text": "sponsor"}, {"boundingBox": [388, 1265, 417, 1265, 418, 1293, 389, 1293], "text": "in"}, {"boundingBox": [422, 1265, 499, 1265, 500, 1294, 423, 1293], "text": "which"}, {"boundingBox": [505, 1265, 664, 1265, 665, 1294, 505, 1294], "text": "pioglitazone"}, {"boundingBox": [669, 1265, 719, 1265, 720, 1294, 670, 1294], "text": "was"}, {"boundingBox": [725, 1265, 904, 1264, 905, 1294, 726, 1294], "text": "administered."}, {"boundingBox": [914, 1264, 961, 1264, 962, 1294, 916, 1294], "text": "The"}, {"boundingBox": [966, 1264, 1038, 1263, 1039, 1294, 968, 1294], "text": "study"}, {"boundingBox": [1043, 1263, 1097, 1263, 1098, 1294, 1045, 1294], "text": "was"}, {"boundingBox": [1102, 1263, 1212, 1263, 1213, 1293, 1104, 1294], "text": "designed"}, {"boundingBox": [1217, 1263, 1246, 1262, 1247, 1293, 1218, 1293], "text": "as"}, {"boundingBox": [1251, 1262, 1355, 1262, 1356, 1293, 1252, 1293], "text": "follows:"}]}, {"boundingBox": [287, 1299, 319, 1299, 317, 1329, 285, 1329], "text": ".", "words": [{"boundingBox": [287, 1299, 307, 1299, 307, 1329, 287, 1329], "text": "."}]}, {"boundingBox": [321, 1299, 1258, 1300, 1257, 1332, 320, 1331], "text": "BBN was given to male Fisher rats in their drinking water for four weeks.", "words": [{"boundingBox": [331, 1300, 390, 1301, 390, 1329, 330, 1329], "text": "BBN"}, {"boundingBox": [404, 1301, 454, 1301, 454, 1330, 403, 1330], "text": "was"}, {"boundingBox": [460, 1301, 533, 1301, 533, 1331, 460, 1330], "text": "given"}, {"boundingBox": [538, 1301, 564, 1301, 565, 1331, 538, 1331], "text": "to"}, {"boundingBox": [570, 1301, 634, 1301, 634, 1331, 570, 1331], "text": "male"}, {"boundingBox": [639, 1301, 718, 1302, 718, 1332, 639, 1331], "text": "Fisher"}, {"boundingBox": [723, 1302, 772, 1302, 773, 1332, 724, 1332], "text": "rats"}, {"boundingBox": [778, 1302, 804, 1302, 804, 1332, 778, 1332], "text": "in"}, {"boundingBox": [810, 1302, 869, 1301, 870, 1332, 810, 1332], "text": "their"}, {"boundingBox": [875, 1301, 984, 1301, 984, 1332, 876, 1332], "text": "drinking"}, {"boundingBox": [989, 1301, 1062, 1301, 1063, 1332, 990, 1332], "text": "water"}, {"boundingBox": [1068, 1301, 1105, 1301, 1106, 1332, 1069, 1332], "text": "for"}, {"boundingBox": [1111, 1301, 1167, 1300, 1168, 1331, 1112, 1332], "text": "four"}, {"boundingBox": [1172, 1300, 1257, 1300, 1258, 1331, 1173, 1331], "text": "weeks."}]}, {"boundingBox": [327, 1337, 704, 1336, 705, 1367, 327, 1368], "text": "Four groups were designated:", "words": [{"boundingBox": [332, 1337, 392, 1337, 393, 1368, 332, 1368], "text": "Four"}, {"boundingBox": [398, 1337, 488, 1338, 488, 1368, 399, 1368], "text": "groups"}, {"boundingBox": [494, 1338, 559, 1338, 559, 1368, 494, 1368], "text": "were"}, {"boundingBox": [565, 1338, 705, 1337, 705, 1366, 565, 1368], "text": "designated:"}]}, {"boundingBox": [328, 1376, 361, 1374, 362, 1402, 329, 1403], "text": ".", "words": [{"boundingBox": [333, 1374, 351, 1373, 353, 1401, 334, 1402], "text": "."}]}, {"boundingBox": [380, 1374, 861, 1372, 862, 1405, 381, 1406], "text": "Pioglitazone 40 mg/kg/day after BBN", "words": [{"boundingBox": [381, 1375, 537, 1374, 538, 1406, 381, 1406], "text": "Pioglitazone"}, {"boundingBox": [544, 1374, 576, 1374, 576, 1407, 544, 1407], "text": "40"}, {"boundingBox": [582, 1374, 719, 1373, 718, 1406, 582, 1407], "text": "mg/kg/day", "confidence": "Low"}, {"boundingBox": [725, 1373, 782, 1373, 781, 1405, 724, 1406], "text": "after", "confidence": "Low"}, {"boundingBox": [788, 1373, 851, 1373, 850, 1404, 787, 1405], "text": "BBN"}]}, {"boundingBox": [378, 1410, 1408, 1409, 1409, 1445, 379, 1446], "text": "The study compound plus BBN (No dosages were specified, but Dr. El-Hage", "words": [{"boundingBox": [381, 1411, 434, 1411, 435, 1445, 383, 1445], "text": "The"}, {"boundingBox": [440, 1412, 515, 1412, 516, 1445, 442, 1445], "text": "study"}, {"boundingBox": [522, 1412, 662, 1412, 663, 1446, 523, 1445], "text": "compound"}, {"boundingBox": [668, 1412, 727, 1412, 729, 1446, 670, 1446], "text": "plus"}, {"boundingBox": [734, 1412, 798, 1413, 799, 1446, 735, 1446], "text": "BBN"}, {"boundingBox": [811, 1413, 868, 1412, 869, 1446, 812, 1446], "text": "(No"}, {"boundingBox": [879, 1412, 982, 1412, 982, 1446, 880, 1446], "text": "dosages"}, {"boundingBox": [988, 1412, 1058, 1412, 1059, 1446, 989, 1446], "text": "were"}, {"boundingBox": [1065, 1412, 1190, 1411, 1190, 1446, 1066, 1446], "text": "specified,"}, {"boundingBox": [1196, 1411, 1244, 1411, 1245, 1445, 1197, 1446], "text": "but"}, {"boundingBox": [1251, 1411, 1301, 1411, 1302, 1445, 1252, 1445], "text": "Dr."}, {"boundingBox": [1308, 1411, 1409, 1410, 1409, 1445, 1308, 1445], "text": "El-Hage"}]}, {"boundingBox": [375, 1447, 1412, 1446, 1412, 1481, 376, 1482], "text": "noted that multiple dosages were studied and the high dose was designed to be", "words": [{"boundingBox": [376, 1449, 452, 1449, 453, 1480, 378, 1480], "text": "noted"}, {"boundingBox": [458, 1449, 511, 1449, 512, 1481, 459, 1480], "text": "that"}, {"boundingBox": [517, 1449, 629, 1449, 629, 1481, 518, 1481], "text": "multiple"}, {"boundingBox": [637, 1449, 739, 1448, 739, 1482, 638, 1481], "text": "dosages"}, {"boundingBox": [745, 1448, 812, 1448, 812, 1482, 745, 1482], "text": "were"}, {"boundingBox": [818, 1448, 914, 1448, 914, 1482, 818, 1482], "text": "studied"}, {"boundingBox": [920, 1448, 969, 1448, 969, 1482, 920, 1482], "text": "and"}, {"boundingBox": [975, 1448, 1020, 1448, 1020, 1482, 975, 1482], "text": "the"}, {"boundingBox": [1026, 1448, 1085, 1448, 1085, 1482, 1026, 1482], "text": "high"}, {"boundingBox": [1097, 1448, 1156, 1448, 1156, 1482, 1097, 1482], "text": "dose"}, {"boundingBox": [1162, 1447, 1219, 1447, 1219, 1481, 1162, 1482], "text": "was"}, {"boundingBox": [1227, 1447, 1337, 1447, 1337, 1481, 1227, 1481], "text": "designed"}, {"boundingBox": [1343, 1447, 1374, 1447, 1373, 1481, 1343, 1481], "text": "to"}, {"boundingBox": [1380, 1447, 1410, 1447, 1410, 1480, 1379, 1481], "text": "be"}]}, {"boundingBox": [380, 1480, 871, 1484, 870, 1517, 379, 1513], "text": "\"equivalent\" to 40 mg/kg pioglitazone )", "words": [{"boundingBox": [380, 1481, 538, 1482, 538, 1515, 381, 1512], "text": "\"equivalent\"", "confidence": "Low"}, {"boundingBox": [544, 1482, 573, 1482, 573, 1515, 544, 1515], "text": "to"}, {"boundingBox": [579, 1482, 609, 1483, 609, 1515, 579, 1515], "text": "40"}, {"boundingBox": [615, 1483, 696, 1483, 696, 1516, 615, 1516], "text": "mg/kg"}, {"boundingBox": [702, 1483, 860, 1484, 860, 1516, 702, 1516], "text": "pioglitazone"}, {"boundingBox": [866, 1484, 870, 1484, 870, 1516, 866, 1516], "text": ")"}]}, {"boundingBox": [377, 1521, 974, 1520, 975, 1554, 378, 1555], "text": "The negative control group received BBN only.", "words": [{"boundingBox": [380, 1522, 427, 1522, 428, 1554, 380, 1553], "text": "The"}, {"boundingBox": [433, 1522, 542, 1523, 543, 1555, 434, 1554], "text": "negative"}, {"boundingBox": [548, 1523, 641, 1523, 641, 1555, 549, 1555], "text": "control"}, {"boundingBox": [647, 1523, 718, 1523, 719, 1555, 647, 1555], "text": "group"}, {"boundingBox": [725, 1523, 833, 1522, 834, 1555, 725, 1555], "text": "received"}, {"boundingBox": [840, 1522, 901, 1521, 902, 1554, 840, 1555], "text": "BBN"}, {"boundingBox": [911, 1521, 973, 1521, 974, 1553, 912, 1554], "text": "only."}]}, {"boundingBox": [328, 1556, 362, 1556, 360, 1587, 327, 1587], "text": ".", "words": [{"boundingBox": [333, 1556, 353, 1556, 353, 1587, 333, 1587], "text": "."}]}, {"boundingBox": [377, 1558, 909, 1560, 908, 1594, 376, 1591], "text": "The positive control group received uracil.", "words": [{"boundingBox": [381, 1558, 427, 1559, 427, 1591, 381, 1590], "text": "The"}, {"boundingBox": [433, 1559, 536, 1561, 537, 1593, 434, 1591], "text": "positive"}, {"boundingBox": [543, 1561, 633, 1562, 633, 1593, 543, 1593], "text": "control"}, {"boundingBox": [639, 1562, 713, 1563, 713, 1593, 640, 1593], "text": "group"}, {"boundingBox": [719, 1563, 826, 1562, 827, 1592, 720, 1593], "text": "received", "confidence": "Low"}, {"boundingBox": [833, 1562, 908, 1561, 909, 1591, 833, 1592], "text": "uracil."}]}, {"boundingBox": [321, 1594, 972, 1595, 971, 1629, 320, 1628], "text": "Duration of daily dosing was 32-weeks after BBN.", "words": [{"boundingBox": [329, 1595, 443, 1597, 443, 1629, 329, 1627], "text": "Duration"}, {"boundingBox": [449, 1597, 481, 1597, 481, 1629, 449, 1629], "text": "of"}, {"boundingBox": [487, 1598, 548, 1598, 548, 1630, 487, 1629], "text": "daily"}, {"boundingBox": [555, 1598, 641, 1598, 641, 1630, 554, 1630], "text": "dosing"}, {"boundingBox": [647, 1598, 698, 1598, 698, 1630, 647, 1630], "text": "was"}, {"boundingBox": [704, 1598, 824, 1597, 824, 1630, 704, 1630], "text": "32-weeks"}, {"boundingBox": [831, 1597, 890, 1596, 889, 1629, 830, 1630], "text": "after"}, {"boundingBox": [896, 1596, 972, 1595, 972, 1629, 896, 1629], "text": "BBN."}]}, {"boundingBox": [326, 1630, 429, 1632, 428, 1666, 325, 1663], "text": "Results:", "words": [{"boundingBox": [331, 1631, 429, 1634, 429, 1665, 330, 1665], "text": "Results:"}]}, {"boundingBox": [329, 1672, 364, 1675, 364, 1703, 328, 1700], "text": ".", "words": [{"boundingBox": [332, 1672, 351, 1673, 348, 1701, 330, 1700], "text": "."}]}, {"boundingBox": [371, 1670, 1412, 1674, 1411, 1708, 370, 1705], "text": "85% of the animals in the pioglitazone and the other sponsor's compound groups", "words": [{"boundingBox": [379, 1671, 439, 1671, 437, 1704, 378, 1704], "text": "85%"}, {"boundingBox": [445, 1671, 473, 1672, 472, 1704, 444, 1704], "text": "of"}, {"boundingBox": [480, 1672, 522, 1672, 521, 1705, 478, 1705], "text": "the"}, {"boundingBox": [529, 1672, 627, 1672, 625, 1706, 527, 1705], "text": "animals"}, {"boundingBox": [633, 1672, 661, 1673, 660, 1706, 632, 1706], "text": "in"}, {"boundingBox": [667, 1673, 708, 1673, 707, 1706, 666, 1706], "text": "the"}, {"boundingBox": [714, 1673, 874, 1673, 873, 1707, 713, 1706], "text": "pioglitazone"}, {"boundingBox": [881, 1673, 927, 1673, 926, 1707, 879, 1707], "text": "and"}, {"boundingBox": [934, 1673, 977, 1674, 976, 1707, 933, 1707], "text": "the"}, {"boundingBox": [983, 1674, 1049, 1674, 1048, 1707, 982, 1707], "text": "other"}, {"boundingBox": [1055, 1674, 1179, 1674, 1178, 1707, 1055, 1707], "text": "sponsor's"}, {"boundingBox": [1186, 1674, 1320, 1674, 1319, 1707, 1185, 1707], "text": "compound"}, {"boundingBox": [1326, 1674, 1412, 1674, 1411, 1707, 1326, 1707], "text": "groups"}]}, {"boundingBox": [376, 1705, 1414, 1706, 1413, 1741, 375, 1740], "text": "had tumor formation. Calculi formation was not confirmed in either group, but", "words": [{"boundingBox": [377, 1706, 427, 1706, 426, 1739, 376, 1739], "text": "had"}, {"boundingBox": [433, 1706, 515, 1706, 514, 1740, 432, 1739], "text": "tumor"}, {"boundingBox": [521, 1706, 665, 1706, 664, 1740, 520, 1740], "text": "formation."}, {"boundingBox": [674, 1706, 768, 1706, 767, 1741, 673, 1740], "text": "Calculi"}, {"boundingBox": [775, 1706, 904, 1706, 903, 1741, 774, 1741], "text": "formation"}, {"boundingBox": [910, 1706, 962, 1706, 961, 1741, 909, 1741], "text": "was"}, {"boundingBox": [968, 1706, 1015, 1706, 1014, 1741, 967, 1741], "text": "not"}, {"boundingBox": [1022, 1706, 1153, 1706, 1152, 1741, 1021, 1741], "text": "confirmed"}, {"boundingBox": [1159, 1706, 1189, 1706, 1188, 1741, 1158, 1741], "text": "in"}, {"boundingBox": [1196, 1706, 1273, 1706, 1272, 1741, 1195, 1741], "text": "either"}, {"boundingBox": [1279, 1706, 1363, 1706, 1362, 1741, 1279, 1741], "text": "group,"}, {"boundingBox": [1370, 1706, 1413, 1706, 1412, 1740, 1369, 1741], "text": "but"}]}, {"boundingBox": [380, 1742, 963, 1741, 963, 1776, 381, 1777], "text": "was looked for using unspecified methodology", "words": [{"boundingBox": [381, 1744, 426, 1744, 426, 1775, 381, 1775], "text": "was"}, {"boundingBox": [432, 1743, 522, 1743, 522, 1776, 432, 1775], "text": "looked"}, {"boundingBox": [528, 1743, 565, 1743, 564, 1777, 528, 1776], "text": "for"}, {"boundingBox": [571, 1743, 641, 1743, 639, 1777, 570, 1777], "text": "using"}, {"boundingBox": [647, 1743, 794, 1742, 792, 1777, 645, 1777], "text": "unspecified", "confidence": "Low"}, {"boundingBox": [800, 1742, 962, 1742, 958, 1777, 798, 1777], "text": "methodology"}]}, {"boundingBox": [374, 1776, 1412, 1778, 1411, 1816, 373, 1815], "text": "15% of the animals in the negative control group had tumor formation, while", "words": [{"boundingBox": [380, 1778, 442, 1778, 441, 1813, 379, 1813], "text": "15%"}, {"boundingBox": [449, 1778, 479, 1778, 478, 1814, 448, 1813], "text": "of"}, {"boundingBox": [486, 1778, 534, 1779, 533, 1814, 484, 1814], "text": "the"}, {"boundingBox": [541, 1779, 644, 1780, 643, 1815, 540, 1814], "text": "animals"}, {"boundingBox": [651, 1780, 681, 1780, 680, 1815, 650, 1815], "text": "in"}, {"boundingBox": [688, 1780, 734, 1780, 732, 1816, 686, 1815], "text": "the"}, {"boundingBox": [741, 1780, 853, 1780, 852, 1816, 739, 1816], "text": "negative"}, {"boundingBox": [860, 1780, 957, 1780, 955, 1816, 859, 1816], "text": "control"}, {"boundingBox": [964, 1780, 1042, 1780, 1040, 1816, 962, 1816], "text": "group"}, {"boundingBox": [1049, 1780, 1101, 1780, 1100, 1816, 1047, 1816], "text": "had"}, {"boundingBox": [1108, 1780, 1191, 1780, 1189, 1816, 1107, 1816], "text": "tumor"}, {"boundingBox": [1198, 1780, 1336, 1779, 1334, 1814, 1196, 1815], "text": "formation,"}, {"boundingBox": [1343, 1779, 1412, 1779, 1410, 1814, 1341, 1814], "text": "while"}]}, {"boundingBox": [380, 1814, 1418, 1815, 1417, 1850, 379, 1849], "text": "approximately 50% of the positive control group presented tumors in the presence", "words": [{"boundingBox": [380, 1817, 561, 1816, 561, 1850, 380, 1849], "text": "approximately"}, {"boundingBox": [567, 1816, 626, 1816, 626, 1850, 567, 1850], "text": "50%"}, {"boundingBox": [632, 1816, 660, 1816, 660, 1850, 632, 1850], "text": "of"}, {"boundingBox": [666, 1816, 706, 1816, 706, 1850, 666, 1850], "text": "the"}, {"boundingBox": [712, 1816, 813, 1816, 813, 1851, 712, 1850], "text": "positive"}, {"boundingBox": [820, 1816, 910, 1815, 910, 1851, 819, 1851], "text": "control"}, {"boundingBox": [917, 1815, 992, 1815, 992, 1851, 916, 1851], "text": "group"}, {"boundingBox": [999, 1815, 1119, 1815, 1118, 1851, 998, 1851], "text": "presented"}, {"boundingBox": [1125, 1815, 1216, 1815, 1215, 1851, 1124, 1851], "text": "tumors"}, {"boundingBox": [1222, 1815, 1247, 1816, 1246, 1851, 1221, 1851], "text": "in"}, {"boundingBox": [1254, 1816, 1294, 1816, 1293, 1851, 1253, 1851], "text": "the"}, {"boundingBox": [1300, 1816, 1418, 1816, 1417, 1850, 1299, 1851], "text": "presence"}]}, {"boundingBox": [381, 1849, 731, 1850, 730, 1887, 380, 1885], "text": "of calculi formation (uracil).", "words": [{"boundingBox": [382, 1851, 404, 1851, 403, 1885, 381, 1885], "text": "of"}, {"boundingBox": [411, 1851, 496, 1850, 495, 1884, 410, 1885], "text": "calculi"}, {"boundingBox": [503, 1850, 627, 1851, 626, 1885, 502, 1884], "text": "formation"}, {"boundingBox": [634, 1851, 730, 1852, 729, 1888, 632, 1885], "text": "(uracil).", "confidence": "Low"}]}, {"boundingBox": [101, 2121, 563, 2122, 562, 2156, 100, 2155], "text": "Confidential - Subject to Protective Order", "words": [{"boundingBox": [101, 2122, 230, 2124, 231, 2156, 102, 2154], "text": "Confidential"}, {"boundingBox": [236, 2124, 253, 2125, 253, 2156, 237, 2156], "text": "-"}, {"boundingBox": [259, 2125, 342, 2125, 343, 2156, 260, 2156], "text": "Subject"}, {"boundingBox": [348, 2125, 369, 2125, 369, 2156, 349, 2156], "text": "to"}, {"boundingBox": [375, 2125, 487, 2124, 488, 2155, 376, 2156], "text": "Protective"}, {"boundingBox": [494, 2124, 562, 2122, 562, 2154, 494, 2155], "text": "Order"}]}, {"boundingBox": [1305, 2120, 1588, 2121, 1587, 2151, 1304, 2150], "text": "TAK-NAUGHP-00080811", "words": [{"boundingBox": [1311, 2122, 1588, 2121, 1587, 2151, 1313, 2151], "text": "TAK-NAUGHP-00080811"}]}, {"boundingBox": [384, 2193, 1314, 2191, 1315, 2231, 385, 2232], "text": "Source: https://www.indup53720boots.ucsf.edu/docs/jsjf0226", "words": [{"boundingBox": [390, 2195, 503, 2196, 503, 2231, 390, 2230], "text": "Source:"}, {"boundingBox": [510, 2196, 1312, 2192, 1313, 2229, 510, 2231], "text": "https://www.indup53720boots.ucsf.edu/docs/jsjf0226", "confidence": "Low"}]}]}]}